10x Genomics, Inc. (LON:0A88)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 5.64B +395.9% |
| Revenue (ttm) | 464.97M -4.3% |
| Net Income | -56.62M |
| EPS | -0.44 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,023 |
| Open | 57.76 |
| Previous Close | 58.58 |
| Day's Range | 56.16 - 60.91 |
| 52-Week Range | 11.17 - 60.00 |
| Beta | 2.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About 10x Genomics
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p... [Read more]
Financial Performance
In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.
Financial numbers in USD Financial StatementsNews
10x Genomics Earnings Call Transcript: Q2 2026
Q2 revenue grew 3% YoY (excluding settlements), driven by strong consumables growth and exceptional demand for the new Atera platform, though instrument sales declined. Full-year guidance was raised, with Atera orders exceeding shipment capacity and AI adoption fueling demand across customer segments.
10x Genomics Earnings release: Q2 2026
10x Genomics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
10x Genomics Quarterly report: Q2 2026
10x Genomics has published its Q2 2026 quarterly earnings report on August 6, 2026.
10x Genomics Reports Second Quarter 2026 Financial Results
PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financi...
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms PLEASANTON, Calif., July 29, 2026 /PRNewswire/ -- ...
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will rep...
10x Genomics Transcript: Transcript
Torex Gold Announces Results of Its 2026 Meeting of Shareholders
Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (O...
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ --...
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerati...
10x Genomics Transcript: Bank of America Global Healthcare Conference 2026
Strong double-digit growth in single-cell and spatial consumables was reported, with the Atera platform launch marking a major milestone. Atera addresses key market bottlenecks, driving high initial demand and expected to consolidate the spatial portfolio over time. Future plans include automation, multi-omics, and expansion into clinical diagnostics.
10x Genomics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 9% year-over-year (excluding settlement revenue), driven by strong consumables growth and the launch of Atera, which received robust pre-order demand. Guidance anticipates flat to modest full-year growth, with Atera shipments expected to drive Q4 revenue.
10x Genomics Earnings release: Q1 2026
10x Genomics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
10x Genomics Quarterly report: Q1 2026
10x Genomics has published its Q1 2026 quarterly earnings report on May 7, 2026.
10x Genomics Reports First Quarter 2026 Financial Results
PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 20...
10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
PLEASANTON, Calif., April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate i...
10x Genomics Proxy statement: Proxy filing
10x Genomics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
10x Genomics Proxy statement: Proxy filing
10x Genomics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor
SAN CARLOS, Calif.--(BUSINESS WIRE)--LiquidCell Dx, a precision diagnostics company building a blood-based platform for tumor microenvironment profiling, today announced the appointment of Mirna Jaros...
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale Debuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the...
10x Genomics Slides: Corporate presentation
10x Genomics has posted slides in relation to its latest quarterly earnings report, which was published on April 17, 2026.
10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended...
Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world to...
PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas
- Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost...
10x Genomics Transcript: TD Cowen 46th Annual Health Care Conference
Double-digit growth in consumables and strong cash flow were achieved despite macro headwinds. Product innovation, especially Flex Apex and Xenium, is driving new customer adoption and volume growth. Biopharma and large-scale projects are key future growth drivers, while competitive intensity has eased.